Stay updated with breaking news from Integrated Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.
Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Looking for the latest Government Contracting News? Check out our story: Jacobs Helps MDA Execute Flight Test of Aegis Missile Defense System in Hawaii. Click
The recent pricing and transmission reforms may lead India to meet its objective of more than doubling the share of gas in its energy basket by making the commodity more affordable to consumers - Issue Date: Apr 30, 2023
Weekly update on stockbroker recommendation, target price, and earnings forecast changes